CN105651752B - The detection method of amyloid protein - Google Patents
The detection method of amyloid protein Download PDFInfo
- Publication number
- CN105651752B CN105651752B CN201610108749.7A CN201610108749A CN105651752B CN 105651752 B CN105651752 B CN 105651752B CN 201610108749 A CN201610108749 A CN 201610108749A CN 105651752 B CN105651752 B CN 105651752B
- Authority
- CN
- China
- Prior art keywords
- carbon
- sample
- quantum dot
- based quantum
- tested
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 47
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title claims description 28
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title claims description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 98
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 96
- 239000002096 quantum dot Substances 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000243 solution Substances 0.000 claims description 53
- 239000000523 sample Substances 0.000 claims description 51
- 239000000178 monomer Substances 0.000 claims description 49
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 230000005284 excitation Effects 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000002189 fluorescence spectrum Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000006184 cosolvent Substances 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008364 bulk solution Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000012488 sample solution Substances 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract description 12
- 238000001917 fluorescence detection Methods 0.000 abstract 1
- 239000007850 fluorescent dye Substances 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 13
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 229910021642 ultra pure water Inorganic materials 0.000 description 10
- 239000012498 ultrapure water Substances 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000003595 spectral effect Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical group [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003575 carbonaceous material Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 description 1
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical group [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910021382 natural graphite Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 239000004038 photonic crystal Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明涉及一种淀粉样蛋白的检测方法。具体而言，本发明是以碳基量子点为荧光探针，利用碳基量子点独特的结构和发光特性而实现的。本发明不仅为淀粉样蛋白聚集检测提出了新的方案，并且避免了传统荧光检测方法中对待测体系造成的干扰。
The present invention relates to a method for detecting amyloid. Specifically, the present invention is realized by using carbon-based quantum dots as fluorescent probes and utilizing the unique structure and luminescent properties of carbon-based quantum dots. The invention not only proposes a new scheme for amyloid aggregation detection, but also avoids the interference caused by the system to be detected in the traditional fluorescence detection method.
Description
Technical field
The present invention relates to the detection methods of amyloid protein, more particularly to utilize carbon-based quantum dots characterization amyloid protein
Method is related to protein structure detection field.
Background technique
The generation of amyloidosis is originated from the false folding of protein, and bodily tissue or device are deposited in the form of precipitating
Official, and directly result in the illnesss such as alzheimer's disease, parkinsonism, rabid ox disease (Cell, 2012,148,1188.).Starch
The specific accumulation process of sample albumen is as follows, and false folding occurs for Proteins In Aqueous Solutions, changes to β-lamellar structure, then assembles
At minimum oligomer and the small oligomer of diffusion-type, annular fibrinogen, fibrinogen, fiber with physiological-toxicity, spot is ultimately formed
Block.Current research hotspot such as the change of detecting and tracking amyloid protein structure, currently, thioflavine T and it is Congo red be the most frequently used
Detect the fluorescence probe (Nature.2011,472,226.) of the process.However, these methods in the detection process can be to system
Generate interference.In order to probe into more detection methods, a variety of nano materials such as: gold nano grain, aggregation-induced emission molecule and
Photonic crystal (Chem.Commun., 2015,51,1866.) etc. receives extensive research.Then the preparation process of these materials is numerous
Trivial and biocompatibility is general, brings big inconvenience for clinical application.
Summary of the invention
The object of the present invention is to provide a kind of methods using carbon-based quantum dots characterization amyloid protein, which can
Effectively detection amyloid levels, can also effectively detect amyloid aggregation dynamic behavior.The method of the present invention is easy, at
This low, at low cost and carbon-based quanta point material good biocompatibility；Detection process does not generate interference to system；It solves and examines now
Survey method is single, detection process introduces the technical bottleneck interfered.
To achieve the above object, technical scheme is as follows:
Present invention firstly provides application of the carbon-based quantum dot in amyloid protein detection.
The application includes at least the cohesion conformation for detecting amyloid protein, dynamic for detecting amyloid aggregation
Mechanics, or for detecting amyloid levels etc..
The present invention also provides a kind of methods of cohesion conformation for detecting amyloid protein, which comprises
1) amyloid protein of cohesion conformation to be determined is combined with carbon-based quantum dot, obtains its spectral signature；
2) amyloid protein of known cohesion conformation is combined with carbon-based quantum dot, obtains predetermined spectral signature；
By comparing step 1) and the resulting spectral signature of step 2), the amyloid egg of the cohesion conformation to be determined is determined
White cohesion conformation；Wherein the spectral signature is assessed with fluorescent spectrometry.
Preferably, the known cohesion conformation includes fibrous conformation.
The present invention also provides a kind of dynamic (dynamical) method of detection amyloid aggregation, the method includes by carbon-based quantum
Point is mixed with the amyloid protein solution for being incubated for different time, and according to the variation of carbon-based quantum dot fluorescence intensity, detection is formed sediment
The kinetics of aggregation behavior of powder sample albumen.
Specifically, the above-mentioned dynamic (dynamical) method of detection amyloid aggregation, comprising the following steps:
1) amyloid protein powder is made into the organic solution being completely dissolved, constant-temperature incubation for a period of time after, be dried with nitrogen,
It is dispersed in ultrapure water and forms certain density amyloid protein aqueous solution；Later, sample is placed in shaking table, constant temperature, constant speed
Aging；
2) quantitative sample is taken out from above-mentioned solution at regular intervals, is instilled tissue culture plate (such as 96 orifice plates), and is added
Enter carbon-based quantum dot solution, is uniformly mixed；It is preferred that at least taking three groups of parallel samples to be tested every time；After taking a little every time, starch
Sample albumen stoste all puts back to shaking table；
3) mixed liquor in tissue culture plate (such as 96 orifice plates) is placed in Fluorescence Spectrometer, setting excitation and transmitted wave
It is long, measure the fluorescence intensity of corresponding time carbon-based quantum dot；
4) using the time as abscissa, fluorescence intensity is ordinate, and the fluorescence intensity for drawing carbon-based quantum dot changes over time
Tendency chart is fitted data, obtains the amyloid aggregation behavior dynamics curve of carbon quantum dot detection.
The above-mentioned dynamic (dynamical) method of detection amyloid aggregation, wherein
Step 1) the organic solution is hexafluoroisopropanol (HFIP).
Step 1) the amyloid protein concentration of aqueous solution is 5-100 μM.
Step 2) the certain time interval are 10-60min.
The concentration of step 2) the carbon-based quantum dot solution is 0.5-5mg/mL.
The excitation wavelength of the step 3) fluorescence spectrum is in 350nm between 450nm, and launch wavelength is in 450nm to 550nm
Between；Preferably, the excitation wavelength of the fluorescence spectrum is 400nm, launch wavelength 500nm.
The present invention also provides a kind of for detecting the kit of amyloid levels, and the kit includes carbon-based quantum
Point.
Preferably, the kit includes the carbon-based quantum dot solution of 0.5-5mg/mL；Preferably, the kit includes
The carbon-based quantum dot solution of 1-2mg/mL.
The present invention also provides a kind of methods for detecting amyloid levels, and this method is using carbon-based quantum dot as probe
Fluorescence spectrum detection method.
The excitation wavelength of fluorescence spectrum of the present invention is in 350nm between 450nm, and launch wavelength is in 450nm to 550nm
Between.Preferably, the excitation wavelength of the fluorescence spectrum is 400nm, launch wavelength 500nm.
The method of detection amyloid levels of the present invention, the system of drafting, sample prepare liquid including standard curve
Standby and quick detection.
The sample prepare liquid includes cerebrospinal fluid, blood etc..
Specifically, the method for the detection amyloid levels, the drafting of standard curve the following steps are included:
1) the carbon-based quantum dot solution of 1mg/mL is prepared；
2) A β powder is made into the solution of 1mg/mL, solvent is hexafluoroisopropanol (HFIP)；After being incubated for 3 hours in 37 DEG C,
It is dried with nitrogen, with the dimethyl sulfoxide (DMSO) of 1% volume content for cosolvent, being dispersed in formation concentration in ultrapure water is respectively
6 parts of A beta monomers solution of 50mg/mL, 100mg/mL, 150mg/mL, 200mg/mL, 250mg/mL, 300mg/mL；Take above-mentioned 6 parts
It each 100 microlitres of solution, is mixed in 96 orifice plates with the carbon-based quantum dot solution of 100 microlitres of 1mg/mL respectively；Later, it is placed in fluorescence
In spectrometer, the fluorescence intensity of carbon-based quantum dot is measured, sets excitation wavelength as 400nm, launch wavelength 500nm；It is mono- with A β
Body content mg/mL is abscissa, and fluorescence intensity level (a.u.) is ordinate, draws A beta monomers standard curve.
Shown in the A beta monomers standard curve such as Fig. 4 (a) drawn.
Its equation of linear regression is Y=ax+b, and coefficient R 0.9557, wherein x represents the concentration mg/mL of A beta monomers,
Y represents fluorescence intensity level (a.u.)；A=-5.2, b=1829.5.
Specifically, it is described detection amyloid levels method, wherein the preparation of sample prepare liquid the following steps are included:
Sample to be tested (such as cerebrospinal fluid, blood etc.) is appropriately processed, after removing interfering substance, retain amyloid egg
It is white, to obtain sample prepare liquid.
Specifically, it is described detection amyloid levels method, wherein quickly detection the following steps are included:
1) the carbon-based quantum dot solution of 1mg/mL is prepared；
2) 100 microlitres of above-mentioned sample prepare liquid and the carbon-based quantum dot solution of 100 microlitres of 1mg/mL is taken to mix in 96 orifice plates
It closes；Later, it is placed in Fluorescence Spectrometer, measures the fluorescence intensity of carbon-based quantum dot, set excitation wavelength as 400nm, transmitted wave
A length of 500nm；Blank control test is done simultaneously, A beta monomers content in measuring samples is calculated as follows:
X=(I-I0)/a
Wherein, x is A beta monomers content in sample to be tested, and I is the florescent intensity value of sample to be tested, I0For blank quantum dot
Florescent intensity value, a are the slope numerical value -5.2 of standard curve.
3) A beta monomers content in normal specimens is compared with A beta monomers content in gained measuring samples, is obtained to sample
The content of abnormal amyloid in product (abnormal amyloid is, for example, fibrillar amyloid)；Specifically, lead to
It crosses step 2) method and obtains A beta monomers content x in normal specimens0, compare, obtained to sample with A beta monomers content x in measuring samples
The content of abnormal amyloid is x in product0-x。
The method of detection amyloid levels described above, wherein A beta monomers content can also be by existing in normal specimens
Technology obtains.
The present invention is generally based on the discovery that carbon-based quantum dot can be used as fluorescence probe and combine with amyloid protein, utilizes
The unique structure of carbon-based quantum dot and the characteristics of luminescence, tripe systems are as amyloid protein (such as monomer or threadiness) is to carbon-based quantum dot
Fluorescence intensity it is different and realize.
Carbon-based quantum dot is a kind of novel quasi-zero dimension nano material, it is by agraphitic carbon particle or several layers of to be less than
The graphene film of 100nm constitutes (Science, 2008,320,356.).Movement of the carbon-based quantum dot internal electron in all directions
All limited to, quantum confinement effect is significant, electronics, photoelectricity and in terms of have peculiar property.Carbon-based quantum
Point surface functional group abundant imparts it, and (electrostatic interaction, hydrogen bond, π-π interact with amyloid protein interaction
Deng) ability, in addition, these functional groups and tripe systems are as the active force power of amyloid protein (monomer or fiber) is with albumen structure
The change of elephant and change.The difference of these interaction forces can be embodied in the fluorescence intensity of carbon-based quantum dot.Therefore, pass through survey
The fluorescence intensity feature of fixed carbon-based quantum dot can determine whether amyloid protein conformational characteristic.
Carbon-based quantum dot of the present invention can also can voluntarily be prepared by prior art preparation.
Such as the preparation method of the carbon-based quantum dot includes: to take a certain amount of carbon-based material, is mixed with strong oxidizer, instead
Ying Hou will obtain product filtering, centrifugation and dialysis, can be obtained carbon-based quantum dot.
Preferably, the carbon-based material is natural graphite, carbon fiber.
Preferably, the strong oxidizer is sodium nitrate, the concentrated sulfuric acid.
Preferably, carbon-based quantum dot effective concentration is 0.5~5mg/mL.
A kind of preparation method of carbon-based quantum dot is given in the examples below.
Amyloid protein of the present invention includes amyloid beta (A β), amylin, alpha-synapse albumen, poly glutamy
Amine, PrPC, TDP43 albumen, insulin, α B- crystallin, lysozyme etc..Preferably, the amyloid protein is the shallow lake β
Powder sample albumen (A β).It is further preferred that the amyloid protein is amyloid beta 1-42 (A β42)
The amyloid A β42, sequence are as follows: DAEFR HDSGY EVHHQ KLVFF AEDVG SNKGA IIGLM
VGGVV IA。
Compared with prior art, the invention has the benefit that
Carbon-based quanta point material used in the method for detection amyloid aggregation behavior of the present invention is at low cost, biology
Compatibility is good, provides possibility for application in vivo.In addition, the present invention is different from traditional detection method, to shallow lake in detection
The aggregation system of powder sample albumen does not have an impact.
Detailed description of the invention
Fig. 1 is transmission electron microscope (TEM) photo of carbon-based quantum dot prepared by the embodiment of the present invention 1.
Fig. 2 is the fluorescence spectrum of carbon-based quantum dot prepared by the embodiment of the present invention 1.
Fig. 3 is the size distribution of carbon-based quantum dot prepared by the embodiment of the present invention 1.
Fig. 4 is detection of the carbon-based quantum dot to amyloid beta monomer and fiber.
Fig. 5 is detection of the carbon-based quantum dot to amyloid beta difference fiber content.
Fig. 6 is detection of the carbon-based quantum dot to amyloid beta kinetics of aggregation.
Fig. 7 is detection of the carbon-based quantum dot to amyloid beta kinetics of aggregation.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment.Particular technique is not specified in embodiment
Or condition person, according to the literature in the art described technology or conditions, or carried out according to product description.Agents useful for same
Or production firm person is not specified in instrument, is conventional products that can be commercially available by regular channel.
Unless specifically stated otherwise, the solvent of aqueous solution used is sterile ultra-pure water solution in following embodiment.
Unless specifically stated otherwise, reagent used in following embodiment is analytical reagents.
Embodiment 1: the preparation of carbon-based quantum dot
1) 1g graphite powder is mixed with the 200mL concentrated sulfuric acid and 40g sodium nitrate, is cooled to zero degree.Then, it is slowly added to 4g Gao Meng
Sour potassium, temperature are maintained at 10 DEG C, are vigorously stirred.
2) said mixture after mixing evenly, is transferred in 30 DEG C of oil baths, is reacted 50 minutes.And then, temperature is increased
To 140 DEG C, then react 20h.
3) after reacting, product is cooled to room temperature, is diluted with 500mL deionized water, and adjusts pH value to 3 left sides with Na2CO3
It is right.By 0.22 μm of membrane filtration, supernatant is taken.It is placed in a centrifuge, 10000rpm is centrifuged 10 minutes.Finally, with retention
The bag filter of molecular weight 1000Da is dialysed 3 days, and final quantum point is obtained.
Transmission electron microscope can intuitively reflect the size characteristics of carbon-based quantum dot, and Fig. 1 is that embodiment 1 is made carbon-based
Transmission electron microscope (TEM) photo of quantum dot.Fig. 3 is the size point of carbon-based quantum dot prepared by the embodiment of the present invention 1
Cloth.It can be seen from the figure that the carbon-based quantum dot being prepared is the nanoscale twins of 5nm size.
Fluorescence spectrum can reflect the fluorescent characteristic of material, as shown in Fig. 2, the fluorescence spectrum of obtained carbon-based quantum dot.
Embodiment 2: detection of the carbon-based quantum dot to amyloid beta monomer and fiber
1) detection of the carbon-based quantum dot to amyloid beta monomer
A β powder is made into hexafluoroisopropanol (HFIP) solution of 1mg/mL, 37 DEG C after being incubated for 3 hours, are dried with nitrogen, with
The dimethyl sulfoxide (DMSO) of 1% volume content is cosolvent, and being dispersed in ultrapure water and forming concentration is respectively 50mg/mL,
6 parts of A beta monomers solution of 100mg/mL, 150mg/mL, 200mg/mL, 250mg/mL, 300mg/mL.Take above-mentioned 6 parts of solution each
It 100 microlitres, is mixed in 96 orifice plates with the carbon-based quantum dot solution of 100 microlitres of 1mg/mL respectively.Later, it is placed in Fluorescence Spectrometer
In, the fluorescence intensity of carbon-based quantum dot is measured, sets excitation wavelength as 400nm, launch wavelength 500nm.Obtain carbon-based quantum
The fluorescence intensity of point is with A beta monomers concentration curve.Shown in curve such as Fig. 4 (a), carbon-based quantum dot fluorescence intensity is with A beta monomers
The trend of linear reduction is presented in the increase of concentration.
2) detection of the carbon-based quantum dot to amyloid beta fiber
A β powder is made into hexafluoroisopropanol (HFIP) solution of 1mg/mL, 37 DEG C after being incubated for 3 hours, are dried with nitrogen, with
The dimethyl sulfoxide (DMSO) of 1% volume content is cosolvent, is dispersed in the A β solution for forming that concentration is 20 μM in ultrapure water.Its
For A beta monomers dispersion liquid.
A β powder is made into hexafluoroisopropanol (HFIP) solution of 1mg/mL, 37 DEG C after being incubated for 3 hours, are dried with nitrogen, with
The dimethyl sulfoxide (DMSO) of 1% volume content is cosolvent, is dispersed in the A β solution for forming that concentration is 20 μM in ultrapure water.It
Afterwards, sample is placed in shaking table, 37 DEG C of constant temperature, 150rpm constant speed aging, is incubated for 7 days, obtains A beta dispersion liquid.
100 microlitres of the carbon-based quantum dot (1.5mg/mL) synthesized in Example 1, respectively with 100 microlitres of above-mentioned A beta monomers
After the mixing of A beta dispersion liquid, the fluorescence spectra of above two mixed liquor and carbon-based quantum dot is measured.It obtains corresponding
Shown in fluorescence spectrum such as Fig. 4 (b).Illustrate, carbon-based quantum dot goes out difference to the detectability of A beta monomers and A beta, and A beta monomers can
It is substantially reduced carbon-based quantum dot fluorescence intensity, and A beta has no significant effect carbon-based quantum dot fluorescence intensity.
Embodiment 3: detection of the carbon-based quantum dot to amyloid beta fiber content
The preparation method of A beta monomers solution and A beta solution: with embodiment 2.
1) the A beta monomers being prepared and fiber solution are mixed from 0 to 100% according to the mass percent of A beta, is obtained
To A beta monomers/fiber mixed liquor of different proportion.
2) it takes 100 microlitres of above-mentioned solution to mix with 100 microlitres of carbon-based quantum dots (0.8mg/mL) respectively, 96 orifice plates is added
In, set excitation wavelength as 400nm, launch wavelength 450nm.It measures carbon-based in A beta monomers/fiber mixed liquor of different proportion
The fluorescence intensity of quantum dot.As a result as shown in Figure 5.The result shows that the fluorescence intensity of carbon-based quantum dot contains with fiber in mixed liquor
The linear growth trend of the increase of amount.
Embodiment 4: the detection for the amyloid beta kinetics of aggregation that carbon-based quantum dot is 20 μM to concentration
1) A β powder is made into hexafluoroisopropanol (HFIP) solution of 1mg/mL to be dried with nitrogen after 37 DEG C are incubated for 6 hours,
With the dimethyl sulfoxide (DMSO) of 1% volume content for cosolvent, it is dispersed in the A β solution for forming that concentration is 20 μM in ultrapure water.
Later, sample is placed in shaking table, 37 DEG C of constant temperature, 150rpm constant speed aging.
2) 100 microlitres of solution were taken out from above-mentioned solution every 30 minutes, are added in 96 orifice plates, and it is 1mg/ that concentration, which is added,
The carbon-based quantum dot solution of mL is uniformly mixed.Three groups of parallel samples are taken to be tested every time.After taking a little every time, A β stoste is all put
Shaking table is returned to continue to be incubated for.
3) mixed liquor in 96 orifice plates is placed in Fluorescence Spectrometer, measures the fluorescence intensity of carbon-based quantum dot, setting swashs
Hair wavelength is 450nm, launch wavelength 500nm.
4) using the time as abscissa, fluorescence intensity is ordinate, and the fluorescence intensity for drawing carbon-based quantum dot changes over time
Tendency chart is fitted data, obtains the amyloid aggregation behavior dynamics curve of carbon quantum dot detection.Curve is as schemed
Shown in 6.The result shows that the growth kinetics curve of amyloid beta fiber can be successfully obtained using carbon-based quantum dot as probe, it is fine
Dimension reaches the growth platform phase after 12h.
Embodiment 5: the detection for the amyloid beta kinetics of aggregation that carbon-based quantum dot is 50 μM to concentration
1) A β powder is made into hexafluoroisopropanol (HFIP) solution of 1mg/mL to be dried with nitrogen after 37 DEG C are incubated for 6 hours,
With the dimethyl sulfoxide (DMSO) of 1% volume content for cosolvent, it is water-soluble to be dispersed in the A β that formation concentration is 50 μM in ultrapure water
Liquid.Later, sample is placed in shaking table, 37 DEG C of constant temperature, 150rpm constant speed aging.
2) 100 microlitres of solution were taken out from above-mentioned solution every 20 minutes, are added in 96 orifice plates, and it is 2mg/ that concentration, which is added,
The carbon-based quantum dot solution of mL is uniformly mixed.Three groups of parallel samples are taken to be tested every time.After taking a little every time, A β stoste is all put
Return shaking table.
3) mixed liquor in 96 orifice plates is placed in Fluorescence Spectrometer, measures the fluorescence intensity of carbon-based quantum dot, setting swashs
Hair wavelength is 350nm, launch wavelength 450nm.
4) using the time as abscissa, fluorescence intensity is ordinate, and the fluorescence intensity for drawing carbon-based quantum dot changes over time
Tendency chart is fitted data, obtains the amyloid aggregation behavior dynamics curve of carbon quantum dot detection.Curve is as schemed
Shown in 7.The result shows that the growth kinetics curve of amyloid beta fiber can be successfully obtained using carbon-based quantum dot as probe, it is fine
Dimension reaches the growth platform phase after 12h.
Embodiment 6
A method of detection A beta-aggregation behavior the described method comprises the following steps:
1) A β powder is made into 1mg/mL to be dissolved in hexafluoroisopropanol (HFIP), 37 DEG C after being incubated for 3 hours, and nitrogen is blown
It is dry, with the dimethyl sulfoxide (DMSO) of 1% volume content for cosolvent, it is dispersed in ultrapure water.Later, sample is placed in shaking table
In, 37 DEG C of constant temperature, 150rpm constant speed aging.
2) 100 microlitres of solution were taken out from above-mentioned solution every 30 minutes, are added in 96 orifice plates, and it is 1mg/ that concentration, which is added,
The carbon-based quantum dot solution of mL is uniformly mixed.Three groups of parallel samples are taken to be tested every time.After taking a little every time, A β stoste is all put
Return shaking table.
3) mixed liquor in 96 orifice plates is placed in Fluorescence Spectrometer, measures the fluorescence intensity of carbon-based quantum dot, setting swashs
Hair wavelength is 400nm, launch wavelength 500nm.
4) using the time as abscissa, fluorescence intensity is ordinate, and the fluorescence intensity for drawing carbon-based quantum dot changes over time
Tendency chart is fitted data, obtains the amyloid aggregation behavior dynamics curve of carbon quantum dot detection.
Embodiment 7
A method of detection amyloid levels, the preparation of drafting, sample prepare liquid including standard curve and fast
Speed detection；It is specific as follows:
The drafting of the standard curve the following steps are included:
1) the carbon-based quantum dot solution of 1mg/mL is prepared；
2) A β powder is made into the solution of 1mg/mL, solvent is hexafluoroisopropanol (HFIP), and 37 DEG C after being incubated for 3 hours, nitrogen
Air-blowing is dry, and with the dimethyl sulfoxide (DMSO) of 1% volume content for cosolvent, being dispersed in formation concentration in ultrapure water is respectively
6 parts of A beta monomers solution of 50mg/mL, 100mg/mL, 150mg/mL, 200mg/mL, 250mg/mL, 300mg/mL；Take above-mentioned 6 parts
It each 100 microlitres of solution, is mixed in 96 orifice plates with the carbon-based quantum dot solution of 100 microlitres of 1mg/mL respectively；Later, it is placed in fluorescence
In spectrometer, the fluorescence intensity of carbon-based quantum dot is measured, sets excitation wavelength as 400nm, launch wavelength 500nm；It is mono- with A β
Body content mg/mL is abscissa, and fluorescence intensity level (a.u.) is ordinate, draws A beta monomers standard curve.
Shown in the A beta monomers standard curve such as Fig. 4 (a) drawn.
Its equation of linear regression is Y=ax+b, coefficient R 0.9557.Wherein x represents the concentration mg/mL of A beta monomers,
Y represents fluorescence intensity level (a.u.)；A=-5.2, b=1829.5.
The preparation of the sample prepare liquid the following steps are included:
Sample to be tested (such as cerebrospinal fluid, blood etc.) is appropriately processed, after removing interfering substance, retain amyloid egg
It is white, to obtain sample prepare liquid.
The quick detection the following steps are included:
1) the carbon-based quantum dot solution of 1mg/mL is prepared；
2) 100 microlitres of above-mentioned sample prepare liquid and the carbon-based quantum dot solution of 100 microlitres of 1mg/mL is taken to mix in 96 orifice plates
It closes；Later, it is placed in Fluorescence Spectrometer, measures the fluorescence intensity of carbon-based quantum dot, set excitation wavelength as 400nm, transmitted wave
A length of 500nm；Blank control test is done simultaneously, A beta monomers content in sample is calculated as follows:
X=(I-I0)/a
Wherein, x is A beta monomers content in sample to be tested, and I is the florescent intensity value of sample to be tested, I0For blank quantum dot
Florescent intensity value, a are the slope numerical value -5.2 of standard curve.
3) A beta monomers content in normal specimens is compared with A beta monomers content in gained measuring samples, is obtained to sample
The content of fibrillar amyloid in product；
Specifically, A beta monomers content x in normal specimens is obtained by the above method0, with A beta monomers content x in measuring samples
Comparison, the content for obtaining fibrillar amyloid in measuring samples is x0-x。
Embodiment 8
A method of the cohesion conformation of detection amyloid protein, which comprises
1) amyloid protein of cohesion conformation to be determined is combined with carbon-based quantum dot, obtains its spectral signature；
2) amyloid protein of known cohesion conformation is combined with carbon-based quantum dot, obtains predetermined spectral signature；
By comparing step 1) and the resulting spectral signature of step 2), the amyloid egg of the cohesion conformation to be determined is determined
White cohesion conformation.
The Applicant declares that the present invention illustrates the process method of the present invention through the above embodiments, but the present invention not office
It is limited to above-mentioned processing step, that is, does not mean that the present invention must rely on the above process steps to be carried out.Technical field
Technical staff it will be clearly understood that any improvement in the present invention, equivalence replacement and auxiliary element to raw material selected by the present invention
Addition, selection of concrete mode etc., all of which fall within the scope of protection and disclosure of the present invention.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610108749.7A CN105651752B (en) | 2016-02-26 | 2016-02-26 | The detection method of amyloid protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610108749.7A CN105651752B (en) | 2016-02-26 | 2016-02-26 | The detection method of amyloid protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105651752A CN105651752A (en) | 2016-06-08 |
| CN105651752B true CN105651752B (en) | 2019-04-12 |
Family
ID=56491814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610108749.7A Active CN105651752B (en) | 2016-02-26 | 2016-02-26 | The detection method of amyloid protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105651752B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110002428B (en) * | 2018-01-04 | 2023-08-22 | 国家纳米科学中心 | Carbon-based quantum dot for regulating amyloid protein, preparation method and application thereof |
| CN108489941B (en) * | 2018-01-31 | 2021-07-27 | 吉林大学 | Application of bromophenol blue as a probe for the detection of bovine insulin amyloid fibrils and as an inhibitor of bovine insulin amyloid fibrils |
| CN112816533A (en) * | 2020-12-31 | 2021-05-18 | 商丘师范学院 | Beta-amyloid oligomer sensor with copper nanocluster as electrochemical signal probe |
| CN113008850B (en) * | 2021-02-07 | 2022-02-25 | 首都医科大学宣武医院 | Application of diagnosing Alzheimer disease and device for diagnosing Alzheimer disease |
| CN114354560B (en) * | 2022-01-11 | 2024-09-17 | 云南大学 | Fluorescent biosensor for detecting beta-amyloid protein, preparation method and detection method thereof |
| CN115184319B (en) * | 2022-06-21 | 2025-07-25 | 华中科技大学 | Carbon dot for detecting and inhibiting protein aggregation, and preparation and application thereof |
| CN115656117A (en) * | 2022-09-20 | 2023-01-31 | 浙江大学杭州国际科创中心 | A method for monitoring the progress of lysozyme amyloid fibrosis based on cluster luminescence |
| CN115825023B (en) * | 2022-10-08 | 2025-05-16 | 河南工业大学 | A method for determining the content of amyloid fibril protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399314B1 (en) * | 1999-12-29 | 2002-06-04 | American Cyanamid Company | Methods of detection of amyloidogenic proteins |
| CN101832919A (en) * | 2010-05-12 | 2010-09-15 | 中国科学院长春应用化学研究所 | Screening method of medicines for restraining beta-amyloid deposition |
| CN102565020A (en) * | 2012-01-13 | 2012-07-11 | 上海师范大学 | Method for quantitatively detecting protein through quantum dot resonant scattering |
| CN104597019B (en) * | 2015-01-26 | 2018-08-21 | 郑州大学 | A kind of In-situ reaction system based on carbon quantum dot/manganese dioxide nano-plates layer and its application method for detecting glutathione content |
-
2016
- 2016-02-26 CN CN201610108749.7A patent/CN105651752B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Conjugated Quantum Dots Inhibit the Amyloid β (1–42) Fibrillation Process;Garima Thakur等;《International Journal of Alzheimer’s Disease》;20110302;第2011卷;第2页右栏第2段 |
| 基于量子点的易纤维化蛋白检测;梁立平;《中国优秀硕士学位论文全文数据库工程科技I辑》;20140915;第35-36页第3.3.3、3.3.3、3.3.5节，图3.3 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105651752A (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105651752B (en) | The detection method of amyloid protein | |
| Bogdan et al. | Carbohydrate-coated lanthanide-doped upconverting nanoparticles for lectin recognition | |
| Yang et al. | A facile fluorescence assay for rapid and sensitive detection of uric acid based on carbon dots and MnO 2 nanosheets | |
| Wei et al. | Chiral detection using reusable fluorescent amylose-functionalized graphene | |
| Hu et al. | A rapid and sensitive turn-on fluorescent probe for ascorbic acid detection based on carbon dots–MnO 2 nanocomposites | |
| Guo et al. | Green fluorescent carbon quantum dots functionalized with polyethyleneimine, and their application to aptamer-based determination of thrombin and ATP | |
| Qian et al. | Simultaneous detection of multiple DNA targets by integrating dual‐color graphene quantum dot nanoprobes and carbon nanotubes | |
| Liu et al. | A novel aptamer-mediated CuInS 2 quantum dots@ graphene oxide nanocomposites-based fluorescence “turn off–on” nanosensor for highly sensitive and selective detection of kanamycin | |
| CN109187473A (en) | Fluorescence resonance energy transfer based on up-conversion nano material and tetramethylrhodamine is used for the detection of excretion body | |
| Han et al. | A ratiometric nanoprobe consisting of up-conversion nanoparticles functionalized with cobalt oxyhydroxide for detecting and imaging ascorbic acid | |
| CN104826126B (en) | A kind of method for the three component fluorescence hydrogels for preparing high mechanical properties | |
| Ding et al. | Novel fluorescent organic nanoparticles as a label-free biosensor for dopamine in serum | |
| Lu et al. | Conjugated polymer dots/oxalate anodic electrochemiluminescence system and its application for detecting melamine | |
| Jiang et al. | Facile off-on fluorescence biosensing of human papillomavirus using DNA probe coupled with sunflower seed shells carbon dots | |
| Suo et al. | β-Lactoglobulin amyloid fibril-templated gold nanoclusters for cellular multicolor fluorescence imaging and colorimetric blood glucose assay | |
| Jiang et al. | Construction of a pH-sensitive self-assembly in aqueous solutions based on a dansyl-modified β-cyclodextrin | |
| Li et al. | A ratiometric fluorescent composite nanomaterial for RNA detection based on graphene quantum dots and molecular probes | |
| CN110514632A (en) | A Fluorescent Probe of Conjugated Polymer Nanoparticles Based on Fluorescence Resonance Energy Transfer and Its Application in Detection of Glutathione | |
| CN110642839A (en) | Nano probe and preparation method and application thereof | |
| Qu et al. | Detection of surface pH of paper using a chitosan-modified silica fluorescent nanosensor | |
| CN114668860A (en) | Digital lipid nanoparticle and preparation method and application thereof | |
| Gao et al. | Preparation of photoluminescent enzymatic nanosensors for glucose sensing | |
| CN108760695B (en) | A method for quantitative detection of thrombin based on PRET phosphorescence probe | |
| Hu et al. | Construction and comparison of BSA-stabilized functionalized GQD composite fluorescent probes for selective trypsin detection | |
| CN109444103B (en) | Preparation method of PEI functionalized green fluorescent carbon dots and thrombin detection method based on carbon dots |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |